Human Psychopharmacology Clinical and Experimental · 2009 · 125 citations · 88 references
MedicinePharmacologyPsychiatryClinical PharmacologyNeuropharmacologyPsychopharmacologyAntidepressant PharmacologyAntidepressant PharmacotherapyAntidepressant TherapyAntioxidant DefenseOxidative StressReactive Oxygen SpeciesAntioxidant Defense MechanismsAntioxidant Defense SystemsAntioxidant TreatmentGlutathione Peroxidase ActivityLipid Peroxidation MarkersOxidative Stress InjuryReactive Oxygen Species GenerationSuperoxide Dismutase 1
OBJECTIVE: There are numerous reports indicating disturbed equilibrium between oxidative processes and antioxidative defense in patients with depression. Moreover, depressive patients are characterized by the presence of elements of an inflammatory process, which is one of the sources of reactive oxygen species (ROS). In view of the above, it was decided to study both the effect of fluoxetine monotherapy and that of fluoxetine co-administered with acetylsalicylic acid on lipid peroxidation and antioxidative defense in patients with the first depressive episode in their life. METHOD: Seventy seven patients with major depressive disorder (MDD), divided into two groups were included in the study. The first group, consisting of 52 patients, received fluoxetine 20 mg, and the second one, in addition to fluoxetine 20 mg, received 150 mg of acetylsalicylic acid. The activity of antioxidative enzymes, copper-zinc superoxide dismutase (CuZnSOD, SOD1), catalase (CAT), glutathione peroxidase (GPSH-x) and the concentration of malonyldialdehyde (MDA) was determined in erythrocytes, whereas the total antioxidant status (TAS) was determined in the plasma. All parameters were measured before and after three month therapy. RESULTS: The obtained results indicate a significant decrease in the activity of SOD1, CAT and GSHP-x, as well as in MDA concentration after the combined therapy. Also a significant TAS increase was observed after the combined therapy. The study demonstrated that combined therapy with fluoxetine and ASA is characterized by the same efficacy and clinical safety as fluoxetine monotherapy, resulting additionally in improvement of oxidative stress parameters in the patients treated for depression.
88
M. Hamilton · Journal of Neurology Neurosurgery & Psychiatry · 1960 · 32.6K citations · Full text
THE ASSESSMENT OF ANXIETY STATES BY RATING
Max Hamilton · British Journal of Medical Psychology · 1959 · 11.4K citations